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Toll-Like Receptor 3 Ligand Polyinosinic:Polycytidylic
Acid Promotes Wound Healing in Human and
Murine Skin
Qing Lin1,2,6, Li Wang3,6, Youkun Lin4, Xialin Liu1, Xiangrong Ren1, Sijian Wen4, Xiaolin Du3,
Tao Lu3, Sarah Y. Su2, Xiaoping Yang2, Wenlin Huang5, Shiyou Zhou1, Feng Wen1 and Shao Bo Su1
Toll-like receptors (TLRs) are pattern-recognition receptors and have a critical role in both innate and adaptive
responses to tissue injury. Our previous study showed that wound healing was impaired in TLR3-deficient mice.
In this study, we investigated the capacity of the TLR3 agonist polyriboinosinic-polyribocytidylic acid (poly(I:C))
to promote the healing of skin wounds in humans and mice. We found that topical application with poly(I:C)
accelerated the closure of wounds in patients with laser plastic surgery. In a mouse model, topical application of
poly(I:C) markedly enhanced re-epithelialization, granulation, and neovascularization required for wound
closure. Further studies revealed that poly(I:C) treatment resulted in enhanced recruitment of neutrophils and
macrophages in association with upregulation of a chemokine, macrophage inflammatory protein-2 (MIP-2/
CXCL2), in the wounds. The effect of poly(I:C) was abolished in TLR3-deficient mice or by treatment with MIP-2/
CXCL2-neutralizing antibodies. These results suggest a potential therapeutic value of the TLR3 activator
poly(I:C) for wound healing.
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INTRODUCTION
Wound healing of the skin represents a dynamic process
involving re-epithelialization, fibroplasias, and angiogenesis
(Singer and Clark, 1999). These processes are anteceded by
recruitment of leukocytes spatiotemporally and differentially
regulated by chemokines. The expression of chemokine
receptors by resident cells such as keratinocytes and endothe-
lial cells suggests that chemokines may also contribute to the
regulation of epithelialization, tissue remodeling, and angio-
genesis (McKay and Leigh, 1991). Thus, chemokines are in an
exclusive position to integrate inflammatory events and
reparative processes (Gillitzer and Goebeler, 2001). In addition
to chemokines, the repair process is executed and promoted by
complicated signaling network that involves numerous growth
factors and cytokines to regulate the growth, differentiation,
and metabolism of a target cell via paracrine, autocrine,
juxtacrine, or endocrine mechanisms. The usage of transgenic
and gene knockout mice provides important results that reveal
the in vivo function of mediators in wound repair (Werner and
Grose, 2003). The importance of cognate receptors responding
to these mediators in cutaneous wound repair, such as TCRg
(Jameson et al., 2002), TNFR p55 (Mori et al., 2002),
chemokine receptor CXCR2 (Devalaraja et al., 2000), and
CX3CR1 (Ishida et al., 2008), as well as Toll-like receptors
(TLRs), have been demonstrated.
As members of the pattern-recognition receptors that build
the first defense line of the body, mammalian TLRs are linkers
of innate and adaptive responses. TLRs recognize microbial, as
well as endogenous, ligands from necrotic cells to induce
inflammatory responses (Lin et al., 2011b). For example, TLR3
recognizes double-stranded RNAs derived from viruses (Mat-
sumoto and Seya, 2008), and RNA released from damaged
tissue. Ligands contained within endocytosed cells also
activate TLR3 from within the cells (Kariko et al., 2004).
Studies revealed that TLRs are crucial in the response to tissue
injuries. A markedly slower healing of wounds has been
observed in MyD88-deficient mice (Macedo et al., 2007),
whereas the absence of TLR2 decreases inflammation and
improves wound healing (Dasu et al., 2010). A recent study
reported that TLR9 activation by its ligand CpG ODN
accelerated wound healing in mice (Sato et al., 2010). In
addition to MyD88-dependent signaling, Toll/IL-1R domain-
containing adaptor-inducing IFN-b (TRIF) activated by TLR3
was also involved in wound healing based on our previous
See related commentary on pg 1955
& 2012 The Society for Investigative Dermatology www.jidonline.org 2085
ORIGINAL ARTICLE
Received 28 October 2011; revised 27 January 2012; accepted 17 February
2012; published online 10 May 2012
1The State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center,
Sun Yat-sen University, Guangzhou, China; 2Johns Hopkins University
School of Medicine, Baltimore, Maryland, USA; 3Department of
Dermatology, First Affiliated Hospital, Shantou University Medical College,
Shantou, China; 4Department of Dermatology, First Affiliated Hospital,
Guangxi Medical University, Nanning, China and 5The State Key Laboratory
of Oncology in South China, Cancer Center, Sun Yat-sen University,
Guangzhou, China
Correspondence: Shao Bo Su, The State Key Laboratory of Ophthalmology,
Zhongshan Ophthalmic Center, Sun Yat-sen University, 54 S Xianlie Road,
Guangzhou, China. E-mail: shaobosu@yahoo.com
6These authors contributed equally to this work.
Abbreviations: Abs, antibodies; MIP-2, macrophage inflammatory protein-2;
poly(I:C), polyriboinosinic-polyribocytidylic acid; TLR, Toll-like receptor;
TRIF, Toll/IL-1R domain-containing adaptor-inducing IFN-b
findings that skin healing was impaired in TLR3-deficient mice
with defective expression of chemokines and recruitment of
myeloid cells (Lin et al., 2011a). These results raised the
possibility that activation of TLR3 in vivo with its exogenous
agonists may promote wound closure.
To test this hypothesis, we investigated the effect of topical
application with TLR3 agonist polyriboinosinic-polyribocy-
tidylic acid (poly(I:C)), a common injection solution for the
treatment of viral diseases such as chronic viral hepatitis in
clinic, on skin restoration, as well as the underlying
mechanisms. Our results showed that topical application
with poly(I:C) accelerated wound closure in patients with
post laser surgery injury. We also found that in a mouse
model activation of the TLR3 pathway by poly(I:C) promoted
the healing of excisional skin wounds by enhancement of the
production of a chemokine macrophage inflammatory
protein-2 (MIP-2/CXCL2), which recruited myeloid cells to
the wounds for repair. These results indicate a therapeutic
potential for poly(I:C) to promote wound healing in humans.
RESULTS
Effects of poly(I:C) on skin wound healing in patients
To study the clinical effect of poly(I:C) on wound healing, 18
patients with laser surgery skin wounds were enrolled into the
study. Eighteen patients with skin wounds caused by laser
plastic surgery were enrolled into the study. Ethics approval
for the study was granted by the local research ethics
committee. The patients with laser wounds were randomly
divided into saline-treated and poly(I:C)-treated groups. The
solution of poly(I:C; Guangdong Bangmin Pharmaceutical) or
saline were topically applied to wounds once a day, and no
patient showed systemic or local side effects during or after
treatment.
Among 18 patients with laser-caused wounds, 12 patients
underwent laser surgery to remove nevus, 4 patients were
operated to remove nevus of Ota, 1 patient had freckles, and
1 had a tattoo (Table 1). Poly(I:C) application markedly
enhanced skin wound healing as compared with treatment
with saline solution (Table 1 and Figure 1). In the group of
12 patients of nevus surgery (Table 1), 6 patients who
received poly(I:C) treatment had wound closure time of
5.35±1.03 days, whereas the other 6 patients treated with
saline needed 7.35±1.51 days to achieve wound closure.
The difference in 2 days was statistically significant with a
P-value of 0.023.
Topical administration of poly(I:C) enhanced skin wound
healing in mice
To study the basis of the mechanism for the capacity of
poly(I:C) to promote skin wound healing, we used a mouse
model. Four excision wounds with 4mm diameter were
performed symmetrically on the back skin of mice. Two right
side wounds were treated with 1mgml1 poly(I:C) (Sigma)
and two left side wounds were treated with delivery vehicle
(Figure 2a). Wound areas were analyzed throughout the
healing process. The results showed that treatment with
poly(I:C) decreased wound area beginning on day 3 and
became significant on day 5 after injury. Healing was
completed on day 10 following surgery in poly(I:C)-treated
wounds, which was 2 days earlier than in vehicle-treated
wounds (Figure 2b and c). Microscopic examination on day 3
revealed that although the control skin wound displayed
similar granulation tissue and wound gap area as compared
with the poly(I:C)-treated wound (Figure 2d and e), poly(I:C)
markedly enhanced re-epithelialization (Figure 2h and i),
organized granulation tissue formation (Figure 2f and g), and
neovascularization (Figure 2j and k), with a more promoted
effect on day 5. The enhancing effect of poly(I:C) was
not observed after denaturation (Supplementary Figure S1
online), confirming the specificity of the poly(I:C)-promoted
wound healing. However, poly(I:C) failed to enhance wound
healing in TLR3/ mice throughout the 14-day period
Table 1. Effects of topical poly(I:C) application on patient skin wounds
Poly(I:C) Saline
Patient
number Age Wound of
Complete
healing (day) Patient number Age Wound of
Complete
healing (day)
1 43 Nevus 5 1 5 Nevus 7
2 11 Nevus of Ota 5 2 18 Nevus of Ota 10
3 14 Nevus 6 3 14 Tattoo 7
4 17 Nevus of Ota 5 4 19 Nevus of Ota 7
5 9 Nevus 5 5 2 Nevus 5
6 22 Nevus 5 6 35 Nevus 7
7 20 Nevus 4 7 31 Nevus 9
8 48 Nevus 7 8 25 Nevus 9
9 38 Freckle 6 9 17 Nevus 7
Average: 5.3 (days) Average: 7.6 (days)
Abbreviation: Poly(I:C), polyriboinosinic-polyribocytidylic acid.
Wounds in patients receiving laser surgery were treated with poly(I:C) or saline daily until healing.
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(Supplementary Figure S2a and b online) and failed to
enhance re-epithelialization, granulation tissue formation,
and neovascularization (Supplementary Figure S2c online).
We also examined the effect of poly(I:C) on the expression
of TLR3 and its adaptor protein TRIF in wounded skin.
Quantitative PCR showed that TLR3 and TRIF mRNA was
significantly upregulated in wounded skins of wild-type
mice (Figure 2l and Supplementary Figure S3 online).
Wounds with poly(I:C) treatment showed an increase in
the expression of TLR3 and TRIF as compared with samples
tissues without poly(I:C) treatment (Figure 2l). These findings
indicate that poly(I:C) accelerates skin wound healing in a
TLR3-dependent manner.
Poly(I:C) enhanced leukocyte infiltration in skin wounds in mice
We next examined the effect of poly(I:C) on leukocyte
infiltration at the excisional wound sites. The influx of
neutrophils reached the peak on day 1 and gradually reduced
until day 6 in all wounds without poly(I:C) treatment.
Day 0
Saline
Poly(I:C)
Day 5
Figure 1. Therapeutic effects of polyriboinosinic-polyribocytidylic acid
(poly(I:C)) topical application on human skin wounds after laser surgery.
Wounds after laser surgery of nevus on the cheek of patients were shown. The
wounds were treated daily with saline (upper panels) or poly(I:C) (lower
panels) solution for 5 days. Shown is a representative of nine patients from
each group.
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Figure 2. Polyriboinosinic-polyribocytidylic acid (poly(I:C)) accelerated skin wound healing in mice. (a) Topical administration of poly(I:C). Wounds were
created on day 0 and immediately treated with topical application of vehicle on the two wounds on the left or poly(I:C) on the wounds on the right. Thereafter,
animals received the same administration each day until complete skin wound healing. The analyses of the wound area are determined at the indicated time
point. (b) Representative images of wounds treated with phosphate-buffered saline (PBS) or poly(I:C) post injury. (c) Kinetics of wound closure. Wound area
was quantified and is expressed as the percentage of the original wound area. Data are the mean±SEM of n¼ 6 and representative of three independent
experiments. (d–k) Histopathology of wounds. The wounds were harvested for histopathology on days 3, 5, 7, and 10 post injury. On day 3, boxed areas
showed granulation formation, and enlarged images are shown in d and e. (f, g) On day 5, boxed areas showed further granulation formation and (h, i)
re-epithelialization. (j,k) Sections from wounds on day 5 were stained with anti-CD31 antibodies. Representative results were from three independent
experiments with five animals in each group. Bar¼ 100mm. (l) Quantitative reverse transcriptase–PCR (RT-PCR) to assess Toll-like receptor 3 (TLR3) gene
expression in wounded skin at the indicated time points. The relative changes were normalized against the housekeeping gene GAPDH and calculated using
the 2–DDCT method. Results were from three separate experiments performed in duplicate and expressed as mean±SEM of fold increase over control (intact
skin).*Po0.05 poly(I:C)-treated wounds versus PBS-treated wounds.
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Neutrophil infiltration was significantly enhanced by
poly(I:C) treatment (Figure 3a and d). The difference was
pronounced between days 1 and 3 post surgery, with a 41%
increase on day 1 as compared with the wounds treated with
phosphate-buffered saline (PBS; Figure 3a and d). Macro-
phages began to accumulate on day 1 after injury and
reached maximal levels on day 6 (Figure 3b and e). The
number of macrophages was notably increased in poly(I:C)-
treated wounds on days 3 and 6 (Figure 3b and e). In contrast,
CD3þ T cells in the wound site were in small numbers after
injury. The kinetics and extent of CD3þ T-cell recruitment
were similar in poly(I:C)-treated and control wounds (Figure
3c and f). Thus, poly(I:C) specifically promoted the recruit-
ment of neutrophils and macrophages, but not T cells, into
the wounds.
Macrophages in wounds can be divided into alternatively
activated macrophages and ‘‘classically’’ activated macro-
phages (Stein et al., 1992). The classically activated macro-
phages tend to elicit tissue injury, whereas alternatively
activated macrophages exhibit a high endocytic and phago-
cytotic capacity (Goerdt and Orfanos, 1999), promote
angiogenesis (Kodelja et al., 1997), and contribute to wound
healing (Schebesch et al., 1997). A number of markers for the
alternatively activated macrophages including FIZZ1/ RELMa
and YM1 have been identified (Raes et al., 2002). In our
study, there were numerous F4/80 and Ym1 or F4/80 and
FIZZ1 double-positive macrophages in both control and
poly(I:C)-treated wound tissue 6 days after injury (Figure 3g
and h). The number of Ym1- or FIZZ1-positive macrophages
in poly(I:C)-treated wounds was higher than that in control
wounds (Figure 3g and h). However, poly(I:C) treatment
failed to enhance leukocyte accumulation in the wounds of
TLR3/ animals (Supplementary Figure S4 online). These
data indicate that activation of TLR3 by poly(I:C) enhanced
the recruitment of wound healing/alternatively activated/M2
macrophages into the wounds.
Poly(I:C) enhanced chemokine MIP-2/CXCL2 expression
in skin wounds of mice
Markedly enhanced infiltration of neutrophils and macro-
phages implied that chemokine expression might be upregu-
lated in poly(I:C)-treated mouse skin wounds. Quantitative
PCR arrays revealed that poly(I:C) treatment markedly increased
the expression of the genes for MIP-2/CXCL2, MIP-1a/CCL3,
MCP-1/CCL2, and RANTES/CCL5, with an elevated expres-
sion of MIP-2/CXCL2 up to 10.5-fold on day 1 (Figure 4a).
The protein level of MIP-2/CXCL2 was also determined. In
intact skin, MIP-2/CXCL2 protein was below detectable level
(data not shown). The level of MIP-2/CXCL2 protein was sig-
nificantly increased, reaching the peak on day 1, declining on
day 3, and was still detectable until day 6 after injury (Figure 4b).
At every checked point, poly(I:C) significantly enhanced MIP-
2/CXCL2 production. The most notable increase was seen on
day 1, with up to a 2.5-fold increase above the control level
(Figure 4b). MIP-2/CXCL2 is a ligand for the receptor CXCR2
(Jerva et al., 1997). CXCR2 expression was therefore examined
in wounded skin by immunohistochemical staining. CXCR2
protein was detectable in normal skin, with increased expres-
sion in both the dermis and subcutaneous tissue of wounds
particularly after poly(I:C) treatment (Figure 4c). Similar to
protein expression, the CXCR2 mRNA was highly expressed
in wounds on day 1 after injury, which was further enhanced
by poly(I:C) treatment (Figure 4d). However, poly(I:C) treat-
ment failed to upregulate MIP-2/CXCL2 and CXCR2 expres-
sion in TLR3/ mouse wounds (Supplementary Figure S5
online). These data suggest that MIP-2/CXCL2 induced by
poly(I:C) has an important role in the recruitment of myeloid
cells in TLR3-mediated wound healing.
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Figure 3. Polyriboinosinic-polyribocytidylic acid (poly(I:C)) enhanced leukocyte accumulation in skin wounds in mice. Immunofluorescence analysis was
performed on wound samples with antibodies (Abs) against myeloperoxidase (MPO; (a), day 1), F4/80 ((b), day 3), and CD3 ((c), day 6). Bar¼100 mm. The
numbers of (d) neutrophils, (e) macrophages, and (f) T cells per high-power field (hpf) were counted. *Po0.05, poly(I:C)-treated wounds in comparison
with phosphate-buffered saline (PBS)–treated wounds. (g) Day 6 wounds treated with vehicle (upper panels) or poly(I:C) (lower panels) were double stained for
F4/80 (green) and Ym1 (red) in granulation tissue. (h) Double labeling for F4/80 and Fizz1 in granulation tissue of day 6 wounds. Bar¼ 100 mm. Representative
results from three independent experiments with four animals in each group are shown.
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The effect of neutralizing MIP-2/CXCL2 antibody on
poly(I:C)-treated wounds in mice
To further confirm the role of MIP-2/CXCL2 in wound
healing, we treated mouse wounds with anti-MIP-2/CXCL2
antibodies (Abs) before poly(I:C) application. As shown in
Figure 5a, the effect of poly(I:C) on wound closure was
abrogated by neutralizing MIP-2/CXCL2 Ab treatment.
Notably, in poly(I:C)-treated wounds, MIP-2/CXCL2 neutra-
lization also reduced the mRNA expression of monocyte-
specific chemokine MCP-1/CCL2, MIP-1a/CCL3, and
RANTES/CCL5 (Figure 5b), as well as epithelialization,
granulation tissue formation (Figure 5c), angiogenesis, and
macrophage accumulation in the wounds (Figure 5c and d).
These results confirm that MIP-2/CXCL2 is a critical mediator
for poly(I:C)-promoted wound healing.
DISCUSSION
The primary function of the skin is to serve as a protective
barrier against environment insults. Loss of the integrity of
large portions of the skin as a result of injury or illness may
lead to severe disability or even death. The primary goals of
the treatment of wounds are promoting rapid wound closure
and the formation of a functional and aesthetically satisfac-
tory scar (Singer and Clark, 1999). The present study
demonstrates that in the clinic topical treatment with TLR3
agonist poly(I:C) accelerated wound closure in patients. The
mouse model study further showed that topical application of
poly(I:C) promoted wound healing by enhancing re-epithe-
lialization, granulation tissue formation, and angiogenesis
during the proliferative phase. Moreover, poly(I:C) treatment
enhanced inflammatory cell infiltration associated with MIP-
2/CXCL2 upregulation in wild-type mice.
Poly(I:C) was an effective adjuvant for Th1/17 cell
responses (Longhi et al., 2009; Ren et al., 2011). Poly(I:C)
also has important regulatory activity on the production of
proinflammatory cytokines and chemokines (Cavassani et al.,
2008; Liu et al., 2008). In human skin, poly(I:C) induced MIP-
1a or IL-8 production by keratinocytes via TLR3 (Tohyama
et al., 2005; Matsukura et al., 2006). In an in vivo study on
skin wounds, it was found that poly(I:C) was a potent inducer
of proinflammatory cytokines IL-6 and tumor necrosis
factor-a (Lai et al., 2009). Recent reports showed that poly(I:C)
binds to cytosolic receptors including PKR, retinoic acid–-
inducible gene-I (RIG-I), and melanoma differentiation–asso-
ciated antigen 5 (MDA5) in addition to TLR3. In this study,
we found that the stimulatory effect of poly(I:C) was absent in
TLR3/ mice, indicating that TLR3 signaling is critical in
poly(I:C)-enhanced wound healing. Our findings are consistent
with the study by Maheshwari’s group showing that poly(I:C)
enhanced wound healing in rats and mice by upregulating
adhesion molecules, extracellular matrix proteins, and TGF-
b1 (Bhartiya et al., 1992; Sidhu et al., 1996). Our data also
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Figure 4. Polyriboinosinic-polyribocytidylic acid (poly(I:C)) upregulated chemokine expression in mouse wounds. (a) Skin samples were obtained 0, 1, 3,
and 5 days after the injury and chemokine gene expressions were quantified by real-time PCR using RNA from phosphate-buffered saline (PBS)- or
poly(I:C)-treated wounded skin. Results are from three separate experiments performed in duplicate and expressed as the mean±SEM of fold increase over
control (n¼ 5 per group).*Po0.05 poly(I:C)-treated wounds in comparison with PBS-treated wounds as baseline. (b) Macrophage inflammatory protein-2
(MIP-2/CXCL2) in skin wounds on day 1, 3, and 5 post injury measured by ELISA. All results are expressed as ng chemokine per mg total protein recovered
after homogenization of 8mm punch biopsy. (c) Immunohistochemical analysis of CXCR2 levels in the dermis (upper panels) and subcutaneous tissue
(lower panels) of skin wounds on days 0 and 1 post injury. Bar¼100 mm. Representative results from three independent experiments with four animals in
each group are shown. (d) Quantitative reverse transcriptase–PCR (RT-PCR) to assess the expression of CXCR2 mRNA in wounded skin at the indicated time
points. Results are expressed as mean±SEM fold of control (intact skin; n¼ 5 per group). *Po0.05, poly(I:C)-treated wounds versus PBS-treated wounds.
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demonstrate that poly(I:C) promotes wound healing by
activating TLR3 and its signal adaptor TRIF to upregulate
the expression of type I INF (data not shown), as well as the
chemokine MIP-2/CXCL2 to enhance macrophage accumu-
lation in the wounds. To our knowledge, these observations
delineate a previously unreported mechanism by which
poly(I:C) accelerates wound healing.
Leukocyte infiltration is a hallmark of the inflammatory
phase of skin wound healing (Lingen, 2001). The impaired
cutaneous wound healing in mice deficient in CXCR2
(Devalaraja et al., 2000) or mice with morphine administra-
tion were linked to the defective neutrophil recruitment
(Martin et al., 2010). Consistently, our data show that the
stimulatory effect of poly(I:C) on early immune cell recruit-
ment, which might have resulted from elevated MIP-2/CXCL2
expression, leads to a net acceleration in wound healing. We
speculate that as neutrophils migrate into the site by 24 hours
post injury more MIP-1a/CCL3, MCP-1/CCL2, and RANTES/
CCL5 were produced, resulting in a chemoattractant gradient
that is essential for the subsequent recruitment of macro-
phages. It is generally agreed that wound macrophages have
a pivotal role in the transition between inflammation and
repair during cutaneous healing, by virtue of their function as
a rich source of mediators, which are necessary for the
initiation and propagation of new tissue formation in wounds
(Singer and Clark, 1999; Werner and Grose, 2003; Eming
et al., 2007; Schurmann et al., 2010). The notion was
supported by in vivo studies in which depletion of macro-
phages caused impaired collagen deposition (van Amerongen
et al., 2007) and defective wound repair (Leibovich and Ross,
1975). Other studies demonstrated that injection of macro-
phages into healing cutaneous wounds augments the repair
process (Danon et al., 1989). Our study also showed that
macrophages could sustain the angiogenesis cascade under
inflammatory conditions in a positive feedback loop through
the activation of the HMGB1-TLR4 signaling pathway (Lin
et al., 2011c). It is known that alternatively activated
macrophages are a main subpopulation with beneficial effect
on wound healing (Martinez et al., 2009). Our study showed
an increase of Fizz1 and Ym1 double-positive wound-
healing/alternatively activated/M2 macrophages (Raes et al.,
2002; Nair et al., 2003) in poly(I:C)-treated wounds,
suggesting that the enhanced macrophage recruitment may
be a key step in the wound healing promoted by poly(I:C).
Furthermore, we found that neutralization of MIP-2/CXCL2
abolished the effect of poly(I:C) on wound healing, confirm-
ing that poly(I:C)-enhanced macrophage accumulation was
dependent on elevated MIP-2/CXCL2.
Chronic skin wounds affect 6.5 million patients in the
United States (Sen et al., 2009). The immense economic and
social impact of wounds calls for a better understanding of
the biological mechanisms underlying cutaneous wound
complications. In the clinic, the poly(I:C) injection is
currently used as an IFN-a/b inducer for the treatment of
viral diseases such as chronic hepatitis, flu, and herpes zoster.
In our study, topical administration of poly(I:C) solution in
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immunofluorescence staining (CD31 and F4/80) of anti-MIP-2/CXCL2- and control IgG-pretreated wounds on day 5 post injury. Bar¼ 100mm. (d) The number
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treatment. H&E, hematoxylin and eosin.
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patients accelerated skin wound healing as compared with
the saline treatment. These observations indicate the ther-
apeutic effect of poly(I:C) topical administration in human
skin wound and suggest a potential therapeutic value for
other abnormal wound healing.
MATERIALS AND METHODS
Reagents and Abs
Poly(I:C), goat anti-rabbit and anti-rat IgG-peroxidase Abs, and rabbit
anti-goat IgG-peroxidase Ab were purchased from Sigma. TRIzol
reagent and Hoechst 33342 were from Invitrogen (Carlsbad, CA). The
ExScript RT reagent kit was from TaKaRa (TaKaRa Biotechnology, DaLian,
China). Brilliant SYBR Green QPCR Master Mix was from Stratagene
(La Jolla, CA). FITC-conjugated anti-mouse F4/80 and FITC-conjugated
anti-mouse CD3 were from eBioscience (San Diego, CA). Rabbit anti-
mouse CXCR2, goat anti-mouse PECAM-1 (CD31), goat anti-mouse
myeloperoxidase, FITC-conjugated donkey anti-goat, and PE-conjugated
donkey anti-rabbit IgG polyclonal antibodies were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). Rabbit anti-mouse Ym1 polyclonal
antibody was from StemCell Technologies (Vancouver, British Columbia,
Canada). Rabbit anti-mouse Fizz1 was from PeproTech (London, UK).
Anti-mouse MIP-2/CXCL2 mAb and the mouse MIP-2/CXCL2 ELISA
kit were from R&D Systems (Minneapolis, MN). For the clinical trial,
the poly(I:C) injection solution (1mgml1) was purchased from
Guangdong Bangmin Pharmaceutical (JiangMen, China).
Patients and clinical studies
Eighteen patients with skin wounds caused by laser plastic surgery
were enrolled into the study. Ethics approval for the study was granted
by the local research ethics committee. The study was conducted
according to the Declaration of Helsinki Principles and in compliance
with the International Conference on Harmonization Harmonized
Tripartite Guideline for Good Clinical Practice. All patients provided
written informed consent before participation. The radiant flux of the
laser is 11mJ s1, which could create a skin lesion reaching the
dermis. It was a double-blind, within-patient, saline-controlled,
randomized study to investigate the topical efficacy of poly(I:C) on
wound healing. The wounds were digitally photographed to determine
the size of the areas. The laser wounds of nine patients were treated
daily with topical application of poly(I:C) (2mg per 10 10cm2,
1mgml1, in sodium chloride injection solution). As controls, the
other nine patients were daily treated with saline solution. The wounds
were digitally photographed at the indicated time intervals.
Animals
TLR3/ mice were purchased from Taconic Farms (Rockville, MD).
These mice were backcrossed ten or more generations onto the
C57BL/6 background, and were then intercrossed to obtain the
knockout genotypes and wild-type mice. Littermates of both sexes
aged between 8 and 12 weeks old were used in all experiments.
Animals were housed individually in cages under specific pathogen-
free conditions and given water and standard laboratory chow ad
libitum during the experiments. Genotyping of animals was
performed by PCR of DNA obtained from tail biopsies. Primers
were created according to the genotyping protocol (Stock number:
005217) from the Jackson Laboratory (Bar Harbor, ME). Animal care
and all experimental procedures were approved by the Institutional
Laboratory Animal Care and Use Committee.
In vivo wound model
Full-thickness wounds were created and analyzed as described
previously (Lin et al., 2011a). After wound surgery, 20ml 1mgml1
poly(I:C) in PBS were locally applied to the two wounds on the right
side daily, whereas the other two wounds on the left side were
treated with an equal volume of PBS alone as control. These
conducts were paralleled with another two negative control groups
in which the two skin wounds on the left were treated with 20 ml PBS
or 1mgml1 of denatured poly(I:C), which was heated at 95 1C for
5min and cooled immediately on ice, whereas the wounds on the
right were not treated throughout the entire observation period. In
another series of experiments, ahead of being treated with poly(I:C),
the two wounds on the right side were topically applied with 20 ml of
anti-MIP-2/CXCL2-neutralizing polyclonal Ab (endotoxin level:
o0.1 EU per 1 mg of the antibody) or control IgG at a concentration
of 100mgml1 into wild-type mice for 30min. Wounds were
redressed daily, and fresh control or test solutions were applied.
Histopathological and immunohistochemical analyses and
leukocyte infiltration
The procedures were described previously (Lin et al., 2011a). Wound
specimens were fixed and the sections were stained routinely with
hematoxylin and eosin for histological analysis. Immunohistochem-
ical analyses were performed using anti-CXCR2 (or -MIP-2/CXCL2)
Abs. Frozen cryostat sections of skin wound tissues were immuno-
stained with anti-myeloperoxidase, -F4/80, and -CD3 Ab for
neutrophilic granulocytes, macrophages, and T cells, respectively,
and double-color immunofluorescence analysis was performed to
identify the types of Ym1- or Fizz1-positive macrophages.
ELISA
Wound samples were excised and homogenized in 0.4ml lysis
buffer (10mM PBS, 0.1% SDS, 1% Nonidet P-40, and 5mM EDTA)
containing Protease Inhibitors. The homogenates were centrifuged at
12,000 r.p.m. for 15min. Supernatants were used to determine MIP-
2/CXCL2 levels with commercial ELISA kits according to the
manufacturer’s instructions. Total protein in the supernatants was
measured following the Bradford method. The data were expressed
as the target molecule (ng) per total protein (mg) for each sample.
Total RNA isolation and quantitative real-time PCR
Total RNA isolation and quantitative real-time PCR were performed as
described previously (Lin et al., 2011a). Oligonucleotide primers
(Supplementary Table S1 online) were synthesized by Invitrogen
Biotechnology (Shanghai, China). The values for the initial concentra-
tions of unknown samples were calculated using a software (version
1.7) provided with the ABI 7700 system. The tested mRNA expression
in each sample was finally determined after correction with GAPDH
expression. Each measurement of a sample was recorded in duplicate.
Reproducibility and statistical analysis
Laboratory experiments were repeated at least twice. All figures
show pooled data from replicate experiments or representative experi-
ments as indicated. Data are expressed as mean±SEM for the indicated
number of independently performed duplicated experiments. Statistical
significance between means was analyzed by one-way ANOVA or
two-tailed Student’s t test using the SPSS 13.0 version (IBM, Armonk,
NY). A value of Po0.05 was considered statistically significant.
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